IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
Cordes
M
M
Department of Radiology, Universitaetsklinikum Rudolf-Virchow, Berlin, Germany.
Hierholzer
J
J
Schelosky
L
L
Poewe
W
W
Cordes
I
I
Horowski
R
R
Eichstaedt
H
H
Schmidt
D
D
Felix
R
R
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001549:Benzamides / Q000493:pharmacokinetics*; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D011759:Pyrrolidines / Q000493:pharmacokinetics*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology; D015899:Tomography, Emission-Computed, Single-Photon
D000978:Antiparkinson Agents; D001549:Benzamides; D065127:Dopamine D2 Receptor Antagonists; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide